Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Catalyst Biosciences, Inc. (CBIO)

0.3044   0.022 (7.94%) 02-02 16:00
Open: 0.2951 Pre. Close: 0.282
High: 0.3179 Low: 0.2951
Volume: 1,713,435 Market Cap: 11(M)

Technical analysis

as of: 2023-02-02 4:10:51 PM
Overall:       
Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 0.55     One year: 0.75
Support: Support1: 0.2    Support2: 0.16
Resistance: Resistance1: 0.47    Resistance2: 0.64
Pivot: 0.3
Moving Average: MA(5): 0.29     MA(20): 0.38
MA(100): 0.5     MA(250): 0.39
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 20.2     %D(3): 19.8
RSI: RSI(14): 34.9
52-week: High: 1.82  Low: 0.09
Average Vol(K): 3-Month: 862 (K)  10-Days: 840 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CBIO ] has closed below upper band by 49.5%. Bollinger Bands are 146.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 21 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.29 - 0.29 0.29 - 0.29
Low: 0.28 - 0.28 0.28 - 0.28
Close: 0.28 - 0.28 0.28 - 0.28

Company Description

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.

Headline News

Thu, 02 Feb 2023
Is Catalyst Biosciences Inc (CBIO) Stock a Smart Investment Thursday? - InvestorsObserver

Thu, 02 Feb 2023
SHAREHOLDER ALERT: Weiss Law Reminds SHBI, CBIO, AJRD, and SAL Shareholders About Its Ongoing Investigati - Benzinga

Thu, 26 Jan 2023
SHAREHOLDER ALERT: Weiss Law Reminds CBIO, AJRD, SAL ... - PR Newswire

Wed, 25 Jan 2023
Catalyst Biosciences Inc. (CBIO): Is this the Most Sought-After Stock ... - Invest Chronicle

Wed, 25 Jan 2023
Where Will Catalyst Biosciences Inc (CBIO) Stock Go Next After It ... - InvestorsObserver

Tue, 24 Jan 2023
There Is Still Room For Catalyst Biosciences Inc. (CBIO) to Improve ... - The Dwinnex

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 38 (M)
% Held by Insiders 2.116e+007 (%)
% Held by Institutions 26 (%)
Shares Short 536 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.039e+007
EPS Est Next Qtl -1.55
EPS Est This Year -7.91
EPS Est Next Year -4.81
Book Value (p.s.) 0
Profit Margin (%) 367.4
Operating Margin (%) -1
Return on Assets (ttm) 259.3
Return on Equity (ttm) -46.5
Qtrly Rev. Growth 3.23e+006
Gross Profit (p.s.) 0
Sales Per Share 19.1
EBITDA (p.s.) -4.70362e+007
Qtrly Earnings Growth 0.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -49 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales 0.01
Price to Cash Flow 0.45

Stock Dividends

Dividend 0
Forward Dividend 429890
Dividend Yield 0%
Dividend Pay Date 2017-02-12
Ex-Dividend Date 2015-08-19
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.